Related Experiment Video

Updated: May 21, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

[Study on phenotypical activity of isoenzyme CYP3A4 in children]

B I Kantemirova, A Kh Chernysheva, A K Starodubtsev

    Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic]
    |June 30, 2012
    PubMed

    Insights

    Pediatric cytochrome P450 CYP3A4 activity, measured by cortisol metabolite ratios, varies significantly with age and sex. This finding aids in optimizing pediatric drug dosing and preventing adverse reactions.

    Area of Science:

    • Biochemistry
    • Pediatric Pharmacology

    Background:

    • Cytochrome P450 (CYP) enzymes, particularly CYP3A4, play a crucial role in drug metabolism.
    • Understanding CYP3A4 activity in children is essential for safe and effective pharmacotherapy.

    Purpose of the Study:

    • To determine urinary cortisol and 6-beta-hydroxycortisol levels in healthy children.
    • To estimate CYP3A4 activity using the ratio of 6-beta-hydroxycortisol to cortisol.
    • To investigate age and sex-related differences in CYP3A4 activity.

    Main Methods:

    • High-performance liquid chromatography (HPLC) was used to quantify urinary cortisol and 6-beta-hydroxycortisol.
    • CYP3A4 activity was assessed via the 6-beta-hydroxycortisol/cortisol ratio.
    • Analysis included 30 healthy children stratified by age and sex.

    Main Results:

    • CYP3A4 activity was significantly higher in children aged 4-9 years compared to those aged 0-3 years (p<0.001).
    • Female children aged 0-3 years exhibited lower CYP3A4 activity compared to older females and males in the same age group (p<0.05).

    Conclusions:

    • Pediatric CYP3A4 activity demonstrates distinct developmental patterns influenced by age and sex.
    • These findings provide valuable data for refining drug dosage regimens and minimizing adverse drug events in pediatric populations.

    More Related Videos

    An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

    An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

    Published on: December 3, 2020

    Related Concept Videos

    Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

    Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

    Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

    Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

    Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...